|
| | 21-day Caco-2 differentiated barrier ready-to-use kit that allows the evaluation of oral absorption efficiency, oral bioavalability and oral toxicity | | |
|
| Mucus secreting 21-day more permissive barrier and more similar to human intestinal epithelia | | |
|
| MDCKII cells transfected with efflux transporters modeling net transport events of barriers expressing MDR1 and BCRP at high levels | | |
|
| HepG2 single transduced with different CYP450: 3A4, 1A2, 2E1 and 2A6 isoforms to detect metabolite toxicity due to CYP-dependent bio-activation | | |
|
>> UNIQUE WAY TO PROVIDE YOU READY-TO-USE LIVING CELLS |